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Dear Editor , Psoriasis (PsO) and psoriatic arthritis (PsA) are inflammatory disorders. 
Circulating biomarkers of inflammation such as interleukin (IL)‐6, tumour necrosis factor 
(TNF)‐α, and C‐reactive protein (CRP) have been associated with disease severity and 
progression of PsO and PsA.1 Adiponectin and leptin are adipose‐derived cytokines, 
recognized as key regulators of body weight and metabolism.2 Whether circulating levels 
of these inflammatory and metabolic biomarkers may predict the risk of PsA in patients 
with PsO remains unclear. 
We included 180 patients with PsO only and 143 patients with an additional diagnosis of 
PsA from the Psoriatic Arthritis and Psoriasis Follow‐up Study, a multicentre registry at 
Brigham and Women's Hospital, U.S.A. Participant consent was obtained; the study was 
approved by the institutional review board of Brigham and Women's hospital [protocol 
number: 2012‐P‐001325(1)]. 
Patients with PsO and those with PsA were similar in age (median 51 years, interquartile 
range 40–62). Patients with PsA included a higher proportion of men (56·2%) than those 
with PsO (50·0%). Plasma levels of IL‐6, CRP, TNF‐α, leptin, total adiponectin, and high 
molecular‐weight (HMW) adiponectin were assessed by ultrasensitive enzyme‐linked 
immunosorbent assay or immunoturbidimetric assay. Median plasma levels of TNF‐α 
were significantly higher in patients with PsA compared with those with PsO (3·27 vs. 
1·32 pg mL−1, P < 0·001). Furthermore, there was a slight decrease among patients with 
PsA in median total adiponectin (4·66 vs. 5·36 μg mL−1, P = 0·15) and HMW adiponectin 
(2·58 vs. 3·01 μg mL−1, P = 0·12). 
Logistic regression analyses were conducted to calculate the odds ratios (ORs) and 95% 
confidence intervals (CIs) for associations between plasma biomarkers and PsA, 
compared with PsO. Using median plasma levels of each biomarker in the PsO group as 
the cut‐off, patients were separated into high and low subsets. A high TNF‐α level was 
associated with increased odds of PsA (multivariate adjusted OR = 2·25, 95% CI 1·41–
3·61). A significantly inverse association was found between high total adiponectin and 
odds of PsA (multivariate adjusted OR = 0·61, 95% CI 0·39–0·96). An inverse association 
was also found for HMW adiponectin with PsA, although the association became 
 
 
marginally significant after multivariate adjustment (OR = 0·64, 95% CI 0·41–1·01) 
(Table 1). 
Table 1. The association between biomarker plasma level and odds ratio (OR) of psoriatic 
arthritis 
 
• CI, confidence interval. aAdjusted for age, sex, body mass index, smoking and 
alcohol intake status. bCategorical variables were dichotomized based on the 
median biomarker levels of patients with only psoriasis. 
Previously, Chandran et al . identified serum CRP as a potential soluble marker in PsA 
vs. PsO only.3 The potential prognostic value of soluble IL‐6, adiponectin and leptin in 
differentiating PsA from PsO has also been suggested, but significantly elevated leptin 
was found only among female participants.4, 5 Here we did not find a significant 
 
 
association between plasma CRP, IL‐6, or leptin levels and PsA. However, we did note 
significantly increased concentrations of plasma TNF‐α in PsA vs. PsO. Elevated TNF‐α 
has been associated with metabolic dysfunction and increased body adiposity, while 
obesity may lead to low‐grade systemic inflammation, and obese individuals have a high 
risk of PsO and PsA.6 To our knowledge, no previous study has reported a significant 
difference in circulating TNF‐α level between PsA and PsO. 
Adiponectin increases insulin resistance and may play a role in attenuating inflammatory 
activity. Adiponectin can indirectly suppress production of TNF‐α, and has been 
suggested as a negative regulator of PsO progression.2, 7 Proinflammatory cytokines 
such as TNF‐α and IL‐6 may decrease production – and thereby circulating levels – of 
adiponectin.8 We found a significantly inverse association between plasma adiponectin 
level and PsA, consistent with the current understanding of the role of adiponectin in 
inflammatory disease processes. 
We further examined whether smoking, alcohol intake and body mass index modified the 
associations of PsA with plasma biomarkers. We found an inverse association of PsA 
with total or HMW adiponectin only among participants reporting alcohol intake, 
demonstrating significant interactions (P‐value for the interaction = 0·02 for total 
adiponectin and 0·03 for HMW adiponectin). Further research is merited to better 
understand the implications of the interactions for PsA. 
We acknowledge several limitations. Our study was based on a modest sample size in a 
cross‐sectional setting, which would merely suggest the differentiation between PsA and 
PsO by serum biomarkers. We did not collect complete information on PsO and PsA 
treatment, and were not able to adjust for treatment‐related factors. Additionally, we did 
not compare our findings with those for healthy individuals without psoriatic disease, so 
extrapolation of our results to other settings should be cautious. 
In conclusion, high plasma TNF‐α level was associated with increased odds of PsA, and 
adiponectin level was inversely associated with PsA compared with PsO. Furthermore, 
alcohol consumption significantly modified the inverse association between adiponectin 
and the odds of PsA. Further large‐scale investigation in a prospective setting of patients 
 
 
with PsO would be warranted, if a clinically useful screening test is to be developed for 
risk prediction of PsA based on circulating biomarkers. 
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